Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655118 · ClinicalTrials.gov registry record · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
A Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis, sponsored by Telios Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT04655118 is a Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis that is actively recruiting participants, run by Telios Pharma. The registered enrollment target is 121 participants, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04655118, a Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis, is actively recruiting participants, sponsored by Telios Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TL-895
Study Locations (20)
Other
- Border Medical Oncology - East Albury
- Southern Oncology Specialists - Kogarah
- Royal Perth Hospital - Perth
- St Vincent's Hospital Sydney - Sydney
- Chu De Liège - Liège
- Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao Lucas - São Paulo
- University Hospital "St Ivan Rilski" - Sofia
- Military Medical Academy - Sofia
- CH Le Mans - Le Mans
- CHU de Nantes - Hôtel-Dieu - Nantes
- CHU de Nice - Hopital L' Archet II - Nice
- Universitaetsklinikum Carl Gustav Carus Dresden - Dresden
- Marien Hospital Duesseldorf - Düsseldorf
Ohio
- Gabrail Cancer Center - Canton
- University of Cincinnati (UC) Physicians Company, LLC - Cincinnati
- Ohio State University - Columbus
Colorado
- University of Colorado - Aurora Cancer Center - Aurora
Minnesota
- Mayo Clinic - Rochester - Rochester
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-10-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655118
The ClinicalTrials.gov registry entry for NCT04655118 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (38% lower). The listed sponsor is Telios Pharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04655118 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Ohio, Colorado.
Frequently Asked Questions
What is clinical trial NCT04655118 about?
NCT04655118 is a clinical study titled "Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis". This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., havin...
What is the current status of trial NCT04655118?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2020-10-22. Estimated completion is 2025-12-31.
What conditions does trial NCT04655118 study?
This clinical trial studies the following conditions: Myelofibrosis, Indolent Systemic Mastocytosis.
What interventions are being tested in trial NCT04655118?
The interventions under investigation include: Placebo (DRUG), TL-895 (DRUG).
Who is sponsoring clinical trial NCT04655118?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04655118 being conducted?
This trial has 20 study locations across Colorado, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.